CCN2 and Hepatic fibrosis: Consistently, elevated serum ALT level reduced significantly after HepG2 EV treatment (Figure 5D), which also caused a dramatic attenuation of ACTA2 protein production (Figure 5E) and reduced expression of liver fibrosis-associated genes including COL1A1 and CCN2 (Figure 5F).